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Summory
The area under the ttrombin generation curve (the endogenous
tluombin potential; ETP) has been proposed as a parameter for plasma-
based hypercoagulability and to monitor anticoagulant treatment. We
present an ETP assay for the routine laboratory using a centrifugal ana-
lyser. Throughput is30 samples/h, within and between run imprecision
is 4-5.6V0. Suitable substrates were developed for the ranges of
10-50070 and}-l}D7o of normal.
Independent of tissue factor concentration (if >4 pM), the normal
value of the extrinsic ETP is 384.8 t 51.7 nM.min. The intrinsic ETP,
triggered by ellagic acid, is 414 t 41 nM.min.
The ETP is decreased to 15 and 35% of normal by oral anticoagula-
tion (INR 2.5-4.0) and by heparin administration (APTI 1.5-2.5 x
control).
The ETP is increased in untreated subjects with congenital anti-
thrombin deficiency and in women using oral contraceptives. In deep
vein thrombosis (phlebographically confirmed), it is increased by
29.4V0 (extinsic) and 537o (intrinsic). In (angiographically assessed)
coronary artery disease the increase isby l07o andll%o respectively.
lnlroduclion
The plasma system that is responsible for the generation and subse-
quent inhibition of thrombin in clotting blood will cause a tkombotic
tendency when producing too much free thrombin (hypercoagulability)
(l); when it is not active enough (hypocoagulability) a haemonhagic
diathesis ensues. Hyper- or hypocoagulability can be brought about by
a large number of different pathological conditions and there exists a
large spectrum of laboratory tests to locate the underlying cause. To our
knowledge, however, asingle laboratory parameter that is increased in
all forms of hypercoagulability and decreased in all forms of hypocoa-
gulability does not exist. Such a variable would be useful for the detec-
tion of plasma-based thrombotic tendency and for the surveillance of
drug-induced hypocoagulability (cf., blood sugar in diabetes, blood
pressure in hypertension).
Conespondence to: Prof Dr. H. C. Hemker, Maastricht University,
Department of Biochemistry, P.O. Box 616, 6200 MD Maastricht, The Nether-
lands - Tel.: +33 43 3881675; FAX Number: +33 43 3670988
We have surmised before that the area under the thrombin genera-
tion curve (the endogenous thrombin potential, ETP) might be a good
candidate for such a general indicator of coagulability (2-6). The key
issue in proposing a new laboratory parameter for hyper- and hypo-
coagulation is if it is better than the standard, cunently employed stra-
tegies in terms of clinical outcome. Will it minimise recunent thrombo-
sis and bleeding complications in the management of anticoagulation?
Will it predict or indicate the occunence of postoperative thrombosis?
These questions can only be answered after extensive, large scale cli-
nical studies that are impossible to start unless the test can be performed
in the routine clinical laboratory at a sufficient hroughput. Such stu-
dies are unlikely to be started unless preliminary results indicate a fair
chance of success. This article describes a method for the determination
of the ETP in a routine procedure and reports preliminary results in dif-
ferent hyper- and hypocoagulable states.
Moleriols ond Melhods
Volunteers and P atients
Eight groups of subjects were studied:
a) Apparently healtfry males (n = 118), not using drugs known to affect the
coagulation system, inthe ages between 18 and 80 years, (mean age + SD: 53.7
t 18.8) recruited from the laboratory staff, two service clubs and a monastery,
served to establish t e normal range.
b) Adult in-patients, 9 male and 14 female, aged26 to76 yeus (mean age +
SD: 55.9 t 16.7) with phlebographically confrrmed active deep vein ttnombo-
sis (DVT). None of the patients was receiving anticoagulants at the time of
blood sampling.
c) Patients aged 30 to 75 years, 19 male and 7 female, (mean age + SD:
57 .0 x9 3) with angiographically ssessed coronary artery disease (CAD) and
refened for percutaneous transluminal coronary angioplasty (PICA). None of
the patients was anticoagulated, blood was obtained prior to heparin adminis-
trauon.
d) The control group to groups b and c were healthy individuals, aged 30 to
45 years, from the staff of the Tlrombosis Research Institute (London, Eng-
land).
e) Subjects with congenital antithrombin deficiency. Plasma from 8 patients
from two families with type I antithrombin dehciency were tested. Diagnosis
and molecular basis of the deficiency were described in detail elsewhere (7,8).
The thromboplastin time (PT), the activated partial thromboplastin time
(APTT) before and after adding activated protein C, the Thrombotest@ time,
factors V, VII, IX, XL XII, factor X antigen, total and free protein S, protein C
activity and protein C antigen were in the normal range (see ref. 9 for the
methods employed).
f) The family members without antitlrombin deficiency of group e) were
used as a control group. The same determinations were done as in group e) and
were found to be normal.
g) A random selection of 54 patients on long-term oral anticoagulant
treatment.
h) Healthy volunteers (n = 12) that received unfractionated- or low-molecu-
lar-weight heparin.
Materials
Malonyl-o-aminoisobutyryl-arginine para-nitroanllide methyl ester hydro-
chloride (CH,O-CO-CH2-CO-Aib-tug-pNA.HCl; SQ68) was synthesised by
Serbio Laboratories, France (European Patent 88400304:7). The other novel
chromogenic subshates were synthesised by one of the authors (D.T.S.R.) in a
procedure described in detail elsewhere (10, 1l). The ctuomogenic leaving-
group is always para-nitroaniline, the specific absorbency of which is
9.93 mOD per pM per cm light-path at the measuring wavelength of 405 nm.
A solution of Reptilase (Boehringer Mannheim, Germany) was prepared so
that 20 pl, added to I ml of plasma caused aclot in 4 min. Ancrod, the frbrino-
gen clotting enzyme of the Malayan Pit Viper, was the commercial preparation
Arvin@ (Knoll AG, Ludwigshafen, Germany). It was used at a frnal concentra-
tion of 1 U/ml, causing aclotting time of 50-60 s in normal plasma. It has been
reported not to activate clotting factors or platelets (6,12, l3). Protease A, a
metallo-protease purified from Crotalus basiliscw venom was a kind gift of
Pentapharm (Basel, Switzerland).
Thrombotest@ reagent was obained from Nycomed Pharma AS (Oslo,
Norway).
PT and APTT reagents for automated eterminations (ACL 300R automa-
ton) were rabbifbrain thromboplastin and micronised silica and purchased
from Instrumentation Laboratory Limited (Milan, Italy).
Relipidated recombinant human tissue factor solution (200 nM, a kind gift
of Prof. Y. Nemerson, Mount Sinai Medical School, New York, USA) was used
as a standard. Other recombinant human tissue factor preparations were a gift
of Dade Productions (Dtidingen, Switzerland) as was Actin FS@, asuspension
of ellagic acid and soy bean phosphatides.
Tris buffer contains: 0.05 M Tris-HCl (pH 7.35), 0.1 M NaCl and 0.5 gn
bovine serum albumin (BSA). Hepes buffer (pH 7.35) contains: 0.02 M Hepes
NaOH, 0.15 M NaCl and 0.5 gn BSA.
Plasma
Blood was collected on 0.13 M trisodium citrate; nine parts ofblood to one
part of citrate solution Blood was preferentially taken from fasting subjects,
marked turbidity impairing the spectrophotometrical measurement. Samples
were centrifuged twice at 1000 X g, at 15" C for 15 min. For the normal pool,
plasma was pooled from at least 10 healthy donors, and a third centrifugation
was carried out at 4o C, for I h at 23,000 X g. This plasma was stored at
-80" C. It was checked that the clotting factors and the antiproteases were in the
normal range.
C lotting F acto r D eterminations
Thrombotesto imes (TT) were determined manually, after mixing 30 pl of
plasma into 250 pl of Thrombotesto reagent. INR values were calculated as
INR = (TTou,;""rflT"on,r,)102. Thrombotest percentages were read from the refer-
ence curveprovided by the manufacturer.
The activated partial tlromboplastin time (APTT) was determined by mix-
ing 100 pl of plasma with 100 pl of Actin FSo, stining and incubating for
2 min at 3'7' C and recalcifying with 100 pl of a 25 mM CaCl, solution. The
moment of clotting was determined by tilting. In patient groups b, c and d the
PT and APTT were determined on the ACL 300R (Automated Coagulation
Laboratory).
The plasma level of TAT complex was estimated by enzyme-linked immu-
noadsorbent assay using reagents, calibrators and controls from Behring Diag-
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nostics (Marburg,.Gemany). Besides the preassayed commercial control, a
sample assayed previously was run with every batch of assays.
Prothrombin and factor X were measured using a one stage assay with defi-
cient (immunodepleted) plasmas from Biopool AB (Sweden) as a reactant.
The antithrombin activities (Figs. 5 and 7) were determined by measuring
the half-life time of human thrombin added to the samples and comparing it to
the halflife time of thrombin in samples piked with the intemational heparin
standard, as in ref. 14.
The anti-factor Xa activity measurement was performed using the Rota-
chrom Heparin kit on tle ST 888 automaton from Stago (Asnidres, France).
ETP Determination
A: Defibrination
In order to allow measurement of optical density changes, samples were
dehbrinated with Reptilase or Ancrod. Citrated plasma was mixed with 1 :50
volume of the Reptilase or Ancrod solution and incubated for 10 min at 37" C,
then kept on ice for 10 min. The fibrin was wound out on a small plastic spatu-
la. In ten patients with high hbrinogen levels (5-8 mg/ml) and in normal plasma
to which up to 10 mg/ml of fibrinogen was added, this procedure proved ade-
quate. Unlike Reptilase, Ancrod does not cause haemolysis and can be added to
whole blood, rendering dehbrinated plasma directly upon centrifugation. De-
fibrination of large series of samples is the rate limiting step of the procedure.
A dnoughput of 30 samples/h is readily possible.
B: Measurement
The reactions are carried out in a laboratory automaton capable of measur-
ing the course of the optical density at 405 nm at minimally 30 s intervals dur-
ing 12 to 15 min. We used the Cobas Bio and Cobas Fara centrifugal analysers
(F. Hoffmann-La Roche, Basel, Switzerland) for most experiments. A listing of
the required settings of the instruments is available from the authors. The ETP
determinations on plasma during mixed anticoagulation (reported in Fig. 8)
were canied out on the ACL 300R.
The reaction mixture consists of four parts of defibrinated plasma, one part
of (partial) thromboplastin solution and one part of start solution. As a trigger
for the extrinsic system we used recombinant thromboplastin i  a concentration
of about 30 pM. For the intrinsic system I : 2.5 diluted Actin FS@ was used. In
the Cobas machines the volumes were 80 pl ofdefrbrinated plasma (or 75 pl
plasma with 5 pl of a substance to be tested) and 20 pl of the thromboplastin,
without Cat. After 30 s of incubation, which is suffrcient for temperature equi-
libration, thrombin generation is started by adding 20 pl of a prewarmed start
solution containing 0.1 M CaCl, and 3 mM of substrate. In the ACL 300R the
volumes were 1.25 times higher.
After the start of the reaction the optical density at 405 nm is recorded at
intervals of maximally 30 s for at least l2 min. Examples of the curves obtained
are seen in Figs. 1 and 6. (Unless otherwise indicated all OD values are recal-
culated to 1 cm light-path.)
Carry-over between samples was tested by putting one sample of plasma to
which 1 U/ml of unfractionated heparin was added in between four other sam-
ples of the same normal plasma without heparin. At this heparin concentration
the ETP, as determined with SQ68, is immeasurably ow, yet the normal
samples located immediately after the heparin samples were not significantly
lower than the other normal samples in the same run.
To measure the proportionality constant between the OD endJevel (as
defrned in the next section) and the ETP, tlrombin generation curves were also
determined by subsampling according to ref. 6. In short, from the incubation
mixture given above, after starting the reaction with the Ca# solution without
added substrate, l0 pl samples were drawn at 30 s intervals in which the throm-
bin-related amidolytic activity was determined on 52238.
C: Data handling
The centrifugal analysers were connected to a personal computer via an in-
stalled option that makes the results available on a communication li e follow-
ing the RS-232 standard. The data are in the form of a succession of ASCII
characters representing the series of OD readings, the time of the reading is
given by the position in the list, knowing the sampling interval. The data is used
as input for a program (Pascal or Basic), using a function for character extrac-
tion from the RS-232 interface buffer of the pe,rsonal computer and transformed
to a standard format file which gives the OD as a function of time and from
which the ETP can be calculated off-line. Programs for reception-recording on
IBM compatible PCs are available from the authors.
D: Calculation of the substrate converted by free tluombin
The thrombin potential cannot be read direcdy ftom the OD that develops
during the experiment, because tlrombin is not the only enzyme to convert he
substrate. Part of the free tlrombin (F) is ineversibly bound to cr-macroglobu-
lin to form a complex (C) that retains amidolytic activity' Therefore the course
of OD in time that is experimentally obtained has to be split in the part due to
the activity of free tlrombin and the part due to the ormacroglobulin-tluombin
complex. The steady endlevel of the OD-curve due to free tlrombin (hence-
forward called OD endlevel for short) is proportional to the ETP.
The experimentally obtained signal (P) is the sum ofthe signals producedby
free tlrombin (A) and by the ar-macroglobulin-tluombin complex (B), so
P(t) = A(t) + B(t). The velocity of the formation of the or-macroglobulin-
thrombin complex is first order with respect to the concentration of free throm-
bin, so the course of its concentration is proportional to the primitive (= inte-
grated form) of the course of free thrombin (C(t) = t1p1t;6t). If this relation
holds for the course of the enzymes it also holds for the course of the OD due
ro the products o B(t) = kjA(r)dt and P(t) = A(t) + B(t) = A(t) - kjA(r)dr.
Because the sampling time is short compared to the rate of change in the curve,
the integral term in this formula can be replaced by the sum of all previous A's.
Consequently P" = 4, + k(fu + A, +.......+ An-1), or 4, = (l - k)A,r +
(P" - Pn-,). (Time is replaced by the sample number and the time dependent
constant k is adapted to the sampling interval, see also below')
The starting values of P and A are zero, so An can be calculated from the
experimental ODs (i.e. the course of P") if k is known. The constant k is depen-
dent on the functional concentration of cr-macroglobulin, on the kinetic para-
meters of the cr-macroglobulin-thrombin complex and on the sampling inter-
val. It is not necessary to determine k experimentally. It is in the nature of the
process that, from the moment on that no free thrombin is left, \ will not in-
crease further. So from the time series of P a time series of A is calculated with
an assumed value of k. This value is then varied until it renders a steady end-
level of A in the end-phase of the reaction, which is the required OD end-level.
A program to carry out this calculation is available from the authors.
For our normal pool the conection constant (k) required to obtain free-
tluombin curves with zero end-slope was 0.288 t 0,012 min-r, 0.29 min-r there-
fore is a good starting estimate. It should be noticed however, that in the pro-
gram the constant should be adapted to the sampling interval, i.e. 0.5 x 0.29
when this interval is 30 s, etc.
E: Calculation of the ETP from the OD endlevel
Theoretically the relation between the area under the dnombin generation
curve (i.e. the ETP) and the total amount of substrate converted is given by
ETP = A.K.&.,,S (see ref. 4). Application of this formula requires exact
knowledge of IQ and k"., of the substrate in plasma. These are difftcult to ob-
tain due to the instability of thrombin in the presence of natural inlibitors. We
therefore determined the proportionality between the OD endlevel and the ETP
by assessing the ETP independently from athrombin generation curve obtained
by subsampling.
Resulls
Validntion of the Calculation
To validate the calculation of the OD endlevel from the experimen-
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Fig. 1 Optical density traces with normal plasma, effect of ar-macroglobulin
concentration. Normal pooled plasma was triggered with recombinant human
thromboplastin, Msc-Val-Arg-pNA was used as the chromogenic subsfate.
The filled symbols are the recorded OD traces: I untreated normal plasma;
O: normal plasma incubated for 30 min with 1.5 pM protease A, so as to inac-
tivate part of the ar-macroglobulin. The open symbols are the conesponding
virtual OD traces of substrhte conversion by free thrombin, calculated from the
experimental curves (see Methods). The shaded line gives the mean final OD of
these traces, which represents the total amount of product formed by free
tlrombin
plasma gample by adding protease Aftom Crotalus basiliscus venom,
a protein that binds in a l: I stoichiometric complex to the inhibitor
(15). In Fig. I it is seen that neutralisation of 1.5 pM of the inhibitor
significantly reduces the end-slope of the crude signal, which reflects
the formation of less or-macroglobulin+hrombin complex, but leaves
the calculated course of the OD due to free thrombin, and hence the
OD end-level, unaffected. Similar results were obtained when 0.5 to
3.0 pM ofprotease A was added (results not shown).
Selection of a Substrate
We measured the kinetic constants of 78 newly synthesised oligo-
peptide p-nitroanilides (1l) in plasma in which the natural thrombin in-
Table I Kinetic onstants of chromosenic substrates used for measurine the
ETP
Subst/ate , nrcxnDn









MZ Aib AE ptlA (5068)
H Val Arg pNA
M$ Val Arg pNA
H Glu Gly Val Arg pl.lA
H Glu Val Arg pNA
DEMZ Gly Arg pl.lA
B@ Gly Val Arg pNA
HD-Phe Pro Lys pNA
830 0,15 1
1240 023 04
8 2  0 7 9  1 6
3270 3 51 2.9
930 1 44 27
870 173 36




9550 47 1 4
1430 09 1 6
1 5 1 0  1 1  1 3
2 g  4 5  4 6
9 5 9  1 9  3 8
>10 <1 <2
RV: Reaction velocity at 500 pM substrate concentration, relative to tlrombin
action on MZ-Aib-Arg-pNA (SQ68); MZ: maloiric acid monomethyl ester;
DEMZ: diethyl malonic acid monomethyl ester; Msc: 2-(methylsulfonyl)
ethyloxycarbonyl; Boc: tert.-butyloxycarbonyl; *) substrate 2 is not hydrolysed
by factor Xa, the I(- mentioned is the binding constant measured from compe-
titive inhibition of SQ68 conversion
631
Table2 Relation between OD sienal and
substrates
ETP with different clromogenic 400










Mz Ab tus pNA (so68)
H Val Arg pNA
Ms Val Arg pNA
H Glu Gly Val Arg pNA
H Glu Val Arg pNA
DEMZ Gly Arg pNA
Boc Gly Val Arg pNA #
HD Phe Pro Lys pNA #
5 5 1 5 i 2 3 1  1 1 2  6 9 2  2 0 - 1 0 0 0
8 6 8 7 i 6 6 4  1 7 6  4 . 3 9  1 2 ' 6 0 0
1 0 8 8 1 7 6 5  2 , 2  3 5 1  1 0 - 5 0 0
3 2 . 7 t 4 O 5  0 6 6  1 1 6 6  3 0 - > l 0 O
1 6 8 - 4 1 4 9 1  3 4  2 2 7  1 0 - 5 0 0
5 8 6 6 1 1 7 4  1 1 - 8  0 6 5  2 - 1 O O
( 1 2 0 0 )  5 0  0 0 1 4  1 - s 0
( 1 s o 0 0 )  1 0 0  -  0 1  - 2
The hrst column gives the endlevel of the thrombin dependent OD-signal with
a normal pool plasma (mean + SEM; n = 24 or more); the second column gives
the 7o of the initial amount of substrate (500 pM) that is converted in this pro-
cess; the ionversion factor (column 3) is the multiplier to calculate the ETP
from the final OD level; the range gives the ETP values (7o of normal) that can
be reliably measured with that substrate; #:for substrates 7 and 8, the figures for
the normal values have been calculated via the catalytic effrciencies relative to
sQ68
hibitors had been inactivated by heating. We selected those that were
converted by thrombin at a suitable rate, that were not good factor Xa
subsffates and that did not inhibit prothrombin conversion. We retained
those that are also split by factor Xa, with reaction velocities imilar to
those of thrombin (Table 1). The peak concentrations of factor Xa in
clotting plasma re below 5 nM (16) against 100-200 nM for thrombin,
so factor Xa activity will not significantly contribute to the OD signal.
We determined the ETP of normal pool plasma from the area under
the thrombin generation curve, obtained in the classical way by deter-
mining the thrombin concentration i subsamples from plasma in
which tlrombin generates (6) and, with each of the substrates, meas-
ured the OD endJevel caused by free thrombin as obtained via our stan-
dard procedure. This gave the conversion factors from OD end-level to
ETP (Table 2).
Simulation experiments (results not shown) indicate that until 1070
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Fig. 3 Etrect of thromboplastin concentration ETP and prothrombin con-
suflption. Upper frame (A): Relation between tissue factor concentration and
ETP. Lower frame (B): Relation between tissue factor concentration a d pro-
thrombin consumption. I: Human brain thromboplastin; O: Recombinant
tluomboplastin; O: Recombinant thromboplastin plus 1.1 pM phosphatidylse-
rine/phosphatidylcholine (20/80)
ETP and OD end-level is for all practical purposes maintained. This
sets an upper limit of 500 mOD to the OD endlevel. On the other hand
under our experimental circumstances 10rnOD is the lowest end-level
that can be reliably measured. With each subsftate the range of ETP
values that conesponds to endlevels of 10-500 mOD is different, de-
pending upon its kinetic properties. These ranges are shown in Table 2.
Substrates 1-5 are suitable for measurements in a wide range around the
normal level, whereas substrates 6 and 7 can be used to assess anticoag-
ulation with high precision but will underestimate ETPs that are higher
than normal.
We spiked normal plasma with increasing amounts of heparin,
(0-5 U/mD, so as to decrease the thrombin potential over a wide range
and we determined the OD end-level with the different substrates. It is
seen that, depending upon their kinetic properties, each substrate gives
a useful OD signal in a different range of the ETP (Fig. 2).
Tissue Factor
Fig. 3 shows the dependence of the ETP and of prothrombin con-
sumption upon the concentration of tissue factor. Above a limit of
around 3 pM, ETP and prothrombin consumption are independent of
the tissue factor concentration and hardly dependent upon the type of
thromboplastin used. The addition of extra phospholipid does not sig-
nificantly influence the ETP. Because low amounts of tissue factor
probably mimic the physiological situation best (17, 18), we choose as
the standard condition a tissue factor concentration about wice higher
than that at which, in normal plasma, prothrombin would just be maxi-
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Fig 2 OD signal with different substrates at decreasing ETP. Inireasing
amounts of heparin (0-5 IU) were added to normal plasma so as to decrease the
ETP. The endlevels of the thrombin-dependent signals were determined with
different substrates. l: SQ 68; n: Msc-Val-Arg-pNA; O: DEMZ-Gly-tug-





Fig. 6 Optical density traces in samples after heparin injection. The plasmas
were from a volunteer after subcutaneous injection of I mg of Enoxaparin per
kg body weight (72n9. Graphs in descending order: zero time, 12 h,8 h,
1.5 h and 3 h after injection. Msc-Val-Arg-pNA was used as the chromogenic
substrate
when the same normal plasma was tested in different runs on different
days, was on the mean l%o higher: (extrinsic system 4.7V0, intrinsic
5.6V0ln = 581).
Hepes buffer and Tris buffer give the same normal ETP value in the
extrinsic system (403.8 nM.min t 12.4 versus 398.4 nM.min t l4.l;
n = 17, SQ68), in the intrinsic system Hepes buffer may give slightly
lower values than Tris buffer (399.0 t 10.5 nM.min versus 435.2
nM.min t 16.6;n = 17, SQ68).
The ETP in Anticoagulant Trestment
In Fig. 4 we coinpare the ETP with the INR value in patients under
long-term anticoagulation. The ETP decreases with increasing INR, the
conelation between ETP and INR is not rectilinear and relatively loose
(see discussion).
Fig. 5 shows the effect on the APTT and the ETP of increasing con-
centrations ofheparin added to normal pooled plasma. The ETP is sen-
sitive to low concentrations ofheparin, whereas the APTT is not. Fig. 6
gives the OD traces obtained at different intervals after subcutaneous
injection of 1 mg/kg of Enoxaparin, significant reduction of the signal
is still observed 12 h after injection. Fig. 7 shows a plot of the inhibition
of the ETP versus anti-thrombin activity in a series of ex vivo samples
after subcutaneous injection of unfractionated- and low-molecular-
weight heparin. Comparison of the ex vivo data with the in vitro data of
Fig. 5 shows that unfractionated heparin induces an extra anticoagulant
effect that is not accounted for by the heparin activity per se (see
Discussion).
In Fig. 8 the ETP is compared to the relevant data obtained from the
routine laboratory tests in a patient hat was admitted with deep venous
thrombosis and in which treatment with the low molecular weight hep-
arin Fraxiparine was followed by oral anticoagulant treatment. Similar
pictures were seen in 5 other patients, treated with unfractionated he-
parin or low molecular weight heparin. Unlike the conventional tests,
the ETP is seen to reflect he combined effect of both anticoasulants,
The ETP in Thrombotic Tendency and Manifust Thrombotic Disease
We determined the ETP in 8 patients with a thrombotic tendency due
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Fig. 4 The ETP in oral anticoagulation. The plasmas were from 55 randomly
chosen patients on long term oral anticoagulant treatment. Recombinant human
tissue factor was used as a trigger and Msc-Val-Arg-pNA as a substrate The
line represents the best fitting hyperbola (R, = 0./l$)





Fig. 5 Relation of inhibition of ETP and prolongation of APTT with heparin
activity in vitro. To normal pool plasma different amounts of unfractionated
heparin (UFH) and of a low molecular weight heparin (LMWH) were added.
The ETP and APTT were determined and plotted against the anti-tlrombin ac-
tivity of the heparin. l: ETP, low molecular weight heparin; !: ETP, unfrac-
tionated heparin; O: APTT, LMWH; O: APTT, UFH
dependent ofchanges in the activity ofthe thromboplastin. A number of
different hromboplastin preparations gave identical results (results not
shown).
Normnl Values
Under our experimental conditions, plasmas from normal donors
were found to give an OD endlevel of 54.8 t 8.1 mOD (n = 1 18) frorn
SQ68 and 108.1 t 16.8 mOD (n = 84) from Msc-Val-Arg-pNA. With
the conversion constants of Table 2, this represents an endogenous
thrombin potential of 384.8 t 51.7 nM.min and 394.3 t 62.3 nM.min
respectively. The normal value of the ETP in the intrinsic system
appears not significantly higher: 414 + 41 nM.min (SQ68).
The within run imprecision of the determination, i.e. the standard
enor of a single value calculated from 20-24 identical samples deter-
mined in the same run on a Cobas instrument, was about 47o. (extrinsic
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Frg. 7 Inhibition of ETP upon enoxaparin administration. The ETP of sam-
ples obtained after subcutaneous heparin administration is plofted versus anti-
ttuombin activity, expressed in IU. tr: LMWH (R, = 0.816); f: IJFH
(R" = 0.769)
The results are expressed as mean + SEM; Mann-Whitney U-test was used to
compare the group means of the patients to the control; for the values indicated


















coronary artery disease (CAD) and in which the diagnosis was later
confirmed by phlebography and coronary angiography. The ETP trig-
gered via the extrinsic or the intrinsic pathway is significantly elevated
in both conditions (Table 4). The rise being more pronounced in DVT
than in CAD. Neither the PT nor the APTT reflects this change in the
coagulation system. The mean TAT level, a marker for tkombin gener-
ation in vivo, is significantly increased in the DVT group only.
Discussion
The ETP and Clotting Tests
The method presented opens the possibility to assess the area under
the thrombin generation curve (endogenous thrombin potential, ETP) in
the routine haematological laboratory. The ETP represents the amount
of functional thrombin that is transiently present during the plasma-
to-serum conversion and therefore is an overall test of the final result of
the combined activities of the procoagulant- and anticoagulant factors
in the plasma. This prompts the question of how it compares to the PT
and the APTT as an overall test of coagulability. Clotting occurs at the
moment hat about l%o of the plasma protlrombin is converted into
thrombin [about 10 nM, or 1 international unit (2)]. All frbrinogen is
then split in a matter of seconds. So the clotting time represents the lag-
phase before thrombin appears and >907o fthrombin is formed after
the moment of clotting. There is not automatically a close conelation
between the duration of the lag-phase and the amount of thrombin that
develops. Heparin treatment e.g. will not influence the clotting-time in
the extrinsic system but quite efficiently diminishes the amount of
thrombin appearing (19). Antithrombin deficiency does not cause sig-
nificant shortening of PT or APTT (cf. 7, 8).
Unlike clotting times, the ETP reflects not only the first part but the
whole process of thrombin generation and inactivation. In vivo, throm-
bin, by diffusion and convection, will spread around the site ofits for-
mation. The amount of thrombin formed will determine the extent of
haemostatic- and thrombotic reactions in the neighbourhood. Also the
amount of thrombin generating in a forming clot determines its resis-
tance to clot lysis (20,21). We therefore think that the total amount of
thrombin formed is a more relevant parameter than the lagtime of its
formation.
0 5 ' t 0
Time (days)
Fig. 8 The course of ETP, PT, APTT and anti-factor Xa activity during mixed
anticoagulant treafinent. Dashed line: Period of heparin administration (Fraxi-
parine, s.c. twice daily, 92 IU anti-factor Xa activity per kg body weight, ad-
justed dosages o as to keep the anti-factor Xa measurement between 0.5 and
1.0 Iu/rnl). Drawn line: Period oforal anticoagulation. (Prdviscan at an initial
dosage of 20 mg, and adjusted so as to obtain a PT between 30 and 50V0, cone-
sponding ro an INR of 2.0 to 3.5). O: PT; f : APTT; A: ETP; X anti-factor Xa
activity
(7, 8), before prophylaxis by anticoagulation was started (Table 3). The
ETP is significantly increased, roughly proportional to the decrease of
the antithrombin-level.
We also collected plasmas, before anticoagulant herapy was given,
from patients presenting with deep vein thrombosis (DVT) and acute
Table 3 ETP inantithrombin deficiency
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The precise relation between the value of the ETP and the levels of
the different pro- and anticoagulant factors in the plasma remains to be
investigated. Due to the intricate non-linear kinetics of the coagulation
system this relation is necessarily a complicated one' Preliminary stu-
dies show that the amount ofprotluombin converted and the potency of
the antithrombins are major determinants. Ongoing studies how that
the concentrations of the factors II, V, VII, VUI, IX and XI play a role
as well as that of the factors of the APC-system and the anti-thrombins.
In the present study we limit ourselves to showing the feasibility of a
clinical function test based upon the ETP measurement and its conela-
tion with clinical conditions, without a further attempt at functional
interpretation.
The ETP in Anticoagulation
The data in Figs. 4-8 show that the ETP is lowered by oral anticoag-
ulation, by heparin as well as by mixed treatment (Fig. 8). The ETP is
also diminished by addition to normal plasma of hirudin, dermatan sul-
phate, lactobionic acid and other ineversible inhibitors (results not
shown). So far the ETP seems to be an indicator of any anticoagulant
effect.
Comparing ETP values with INR values (Fig. 4), it is seen that the
conelation between ETP and INR is obviously non-linear and relative-
ly loose [Spearman rank conelation coefficient (r,) = 0.778]. Adequate
anticoagulation (lNR 2.5-4.0) conesponds to 65-85V0 inhibition of the
ETP. The essential question of whether the INR or the ETP, is the
better predictor of bleeding and/or etluombosis will require a clinical
trial.
In Fig. 5 the dose response curves of the ETP and the APTT are
shown in normal plasma spiked with increasing doses of heparin. A
prolongation of L5 to 2.5 of the APTT, which is thought o represent
adequate anticoagulation, again conesponds to 65-8570 inhibition of
the ETP. It thus seems that the ranges of anticoagulation, determined
in clinical practice with two different drugs and with two different
methods of control, induce similar ETP values.
Unlike cunent ests, the ETP is sensitive to low levels of anticoagu-
lation; e.g. the effect of I mg/kg Enoxaparin sstill detected 12 h after
subcutaneous injection (Fig. 6, cf. 14). Both for coumarin congeners
and for heparin it has been claimed that low levels of anticoagulation,
not or hardly influencing PT and AF|T, do prevent thrombosis ( ee ref.
22 for a discussion). Probably such medication will affect in the ETP.
The APTT, being sensitive to variations of hepann activity in the
high concentration range, might theoretically serve a useful alarm-func-
tion for over-anticoagulation. Clinical experience however shows that it
does not (23, 24). The explanation isprobably that the APTT is difficult
t0 relate to coagulation factor inhibition (25) and resists traightforward
standardisation (26). Whether the ETP will be better again requires a
clinical trial.
The inhibition ofthe ETP after subcutaneous injection ofunfraction-
ated (UFH)- and low-molecular-weight heparin (LMWH) is plotted
against an indicator ofheparin concentration (anti-thrombin activity) in
Fig. 7. The strict curvilinear relation between ETP-inhibition and he-
parin activity that is found in vitro (Fig. 5) is lost (R, = 0.769 for UFH
and 0.816 for LMWH), indicating that the individual anticoagulant res-
ponse is not determined by the heparin activity alone. After injection of
LMWH the inhibition of the ETP found in vivo scatters around the in
vitro values, after injection of UFH there is an excess inhibition of the
ETP in vivo, possibly caused by the release of tissue factor pathway in-
hibitor (27, 28). If the ETP values are plotted against the anti-factor Xa
activity ofthe plasma samples (expressed in conventional units) similar
conelation coeffibients are found. Because the anti-factor Xa activity,
expressed in I.U. in the conventional way, is about wice overestimated,
the UFH points are spread over about double the heparin activity range
(i.e. 0-0.2 IU), enoneously suggesting the LMWH to be less active than
UFH when plotted on this basis. (see refs 29 and 30 for a discussion of
this phenomenon).
In clinical practice three different ests are used in anticoagulant
treatment: PT for oral anticoagulation, rendered as the INR (31), APIT
for both unfractionated and low-molecular-weight heparin (32) and
anti-factor Xa activity for low molecular weight heparins (33). This
hampers the control of mixed heparin- and oral-anticoagulant therapy.
Fig. 8 shows that the ETP reflects the combined effect ofboth therapies,
whereas the routine laboratory values react primarily to one or the
other of the treatments.
The ETP inThrombosis Prone States andThrombotic Disease
Congenital antithrombin deficiency evidently causes an elevated
ETP flable 3). It has been shown that the ETP measured as the area
under the (manually obtained) thrombin generation curve, is increased
in women using oral contraceptives but not suffering from thrombosis
(34). In a preliminary report using the continuous method here de-
scribed, it is stated that oral contraceptives of three different doses and
types given to 25 healthy volunteers increases the (extrinsic) ETP to
l2l7o of the baseline value, independent of the type of contraceptive.
This increase was accompanied bya signihcant increase of the frbrino-
peptide A levels (35). We could confirm the ircrease of the ETP in
women using oral contraceptives (results not shown). It seems that the
ETP may indeed signal a thrombotic tendency.
It should be noted that there exists a fundamental difference between
the ETP, which shows the potential capacity of the plasma to generate
thrombin, and markers of in vivo thrombin generation like TAT
complexes and F1+2, which show that the mechanism is indeed trig-
gered in the patient. A healthy child with antithrombin (lII) deficiency
e.g. will show a significantly increased ETP but near to normal F1+2
values. An otherwise normal subject with a beginning thrombotic pro-
cess may show increased TAT and Fl+2 levels but near to normal ETP
values.
The data on patients with DVT and CAD show that the ETP is above
normal in the plasma of patients with an active thrombotic process, be
it arterial or venous, than in normal controls. This might represent
either a pre-existing tendency of these plasmas to generate more throm-
bin - which condition then caused. or contributed to. the disease - or it
might reflect changes brought about in the circulating plasma by the
disease process, the two explanations by no means being mutually
exclusive. The high level of TAT complexes found in DVT patients
(Table 4), shows that the circulating blood has been exposed to throm-
bin-activity. Given the positive feedback effects of thrombin on throm-
bin generation (3, 19 and references therein), it is likely that this in
itself enhances the thrombin generating power of the blood. This latter
explanation may be less likely in the case of CAD, where no elevated
TAT complexes are found. Clinical and epidemiological studies will
have to show in how far an increased ETP indeed indicates an increased
thrombotic risk and in how far it is augmented by an ongoing thrombo-
tic process.
We conclude that with the present technique the ETP may be deter-
mined in the clinical routine laboratory and that the limited data avail-
able justify more extensive studies on the suitability of the ETP meas-
urement as a general indicator of anticoagulation the one hand and
as a screening procedure for hypercoaguable states on the other.
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